More than half the world’s population is expected to be overweight or obese by 2035. Excess weight is often linked with cardiovascular disease: It can lead to higher blood pressure or cholesterol, which increases the risk of heart attack and stroke. Now, the makers of the popular weight-loss drug Wegovy are making a case for its use as a treatment option for diseases of the heart and blood vessels.
In a landmark trial of 17,604 overweight and obese patients with heart disease, weekly injections of semaglutide—the active ingredient in Wegovy and its twin Ozempic—for an average of 33 months reduced the risk of heart
→ Continue reading at Wired - Science